Iterum Therapeutics Secures $25M Loan Facility
Ticker: ITRM · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $20.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, debt, loan
TL;DR
Iterum just got a $25M loan from AOP Orphan to keep the lights on.
AI Summary
On October 28, 2024, Iterum Therapeutics plc entered into a Loan Agreement with AOP Orphan Pharmaceuticals GmbH for a principal amount of $25.0 million. This agreement is structured as a senior secured term loan facility, with the initial drawdowns expected to occur on or around November 1, 2024. The funds are intended to support the company's ongoing operations and strategic initiatives.
Why It Matters
This financing provides Iterum Therapeutics with crucial capital to continue its development and commercialization efforts, potentially impacting its ability to bring new therapies to market.
Risk Assessment
Risk Level: medium — The company is reliant on debt financing, which introduces financial risk and obligations.
Key Numbers
- $25.0M — Loan Facility Amount (Provides immediate capital for operations and strategic initiatives.)
Key Players & Entities
- Iterum Therapeutics plc (company) — Borrower
- AOP Orphan Pharmaceuticals GmbH (company) — Lender
- $25.0 million (dollar_amount) — Principal amount of the loan facility
- October 28, 2024 (date) — Date of the Loan Agreement
- November 1, 2024 (date) — Expected date of initial drawdowns
FAQ
What is the purpose of the $25.0 million loan facility?
The loan facility is intended to support Iterum Therapeutics plc's ongoing operations and strategic initiatives.
Who is the lender for this new loan facility?
The lender is AOP Orphan Pharmaceuticals GmbH.
When was the Loan Agreement entered into?
The Loan Agreement was entered into on October 28, 2024.
What type of loan facility is this?
This is a senior secured term loan facility.
When are the initial drawdowns expected?
Initial drawdowns are expected to occur on or around November 1, 2024.
Filing Stats: 880 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2024-11-01 17:10:08
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
- $20.0 million — make a regulatory milestone payment of $20.0 million to Pfizer (the "Milestone Payment") upo
Filing Documents
- itrm-20241028.htm (8-K) — 44KB
- itrm-ex10_1.htm (EX-10.1) — 20KB
- 0000950170-24-120154.txt ( ) — 186KB
- itrm-20241028.xsd (EX-101.SCH) — 26KB
- itrm-20241028_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number. Description 10.1 Promissory Note dated October 28, 2024 from Iterum Therapeutics International Limited to Pfizer Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: November 1, 2024 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer